Get started
Author

Stephen Shuttleworth

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2009 · Florence I. Raynaud, Suzanne A. Eccles, et al. · Molecular Cancer Therapeutics · 277
PDF
Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform
2011 · Timothy P. Heffron, BinQing Wei, et al. · Journal of Medicinal Chemistry · 72
Discovery of Novel PI3-Kinase δ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition
2012 · Brian S. Safina, Stewart Baker, et al. · Journal of Medicinal Chemistry · 68
Pb/U Fractionation during Nd:YAG 213 nm and 266 nm Laser Ablation Sampling with Inductively Coupled Plasma Mass Spectrometry
2000 · Haichen Liu, Oleg V. Borisov, et al. · Applied Spectroscopy · 58
Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf
2012 · Daniel P. Sutherlin, Stewart Baker, et al. · Bioorganic & Medicinal Chemistry Letters · 53
New applications for laser ablation high resolution ICPMS (LA-HR-ICP-MS): Quantitative measurements of gallium diffusion across human root dentin
2000 · A. Mohamad Ghazi, Stephen Shuttleworth, et al. · Journal of Analytical Atomic Spectrometry · 32
Design and Synthesis of Protein Superfamily-Targeted Chemical Libraries for Lead Identification and Optimization
2005 · Stephen Shuttleworth, Richard Connors, et al. · Current Medicinal Chemistry · 22
Gallium Diffusion in Human Root Dentin: Quantitative Measurements by Pulsed Nd:YAG Laser Ablation Combined with an Inductively Coupled Plasma Mass Spectrometer
2000 · A. Mohamad Ghazi, Stephen Shuttleworth, et al. · Journal of Clinical Laser Medicine & Surgery · 22
A Tandem Amino-Cope Rearrangement/Enamine Alkylation Reaction
1997 · Steven Allin, Martin Button, et al. · Synlett · 18
Assessment of laser ablation and sector field inductively coupled plasma mass spectrometry for elemental analysis of solid samples
1998 · Stephen Shuttleworth, Daniel T. Kremser · Journal of Analytical Atomic Spectrometry · 17
Progress in the Design and Development of Phosphoinositide 3-Kinase (PI3K) Inhibitors for the Treatment of Chronic Diseases
2009 · Stephen Shuttleworth, Franck Silva, et al. · Progress in medicinal chemistry · 14
Progress in the Development of Small Molecule Therapeutics Targeting Th17 Cell Function for the Treatment of Immune-Inflammatory Diseases
2011 · Stephen Shuttleworth, Paul Townsend, et al. · Progress in medicinal chemistry · 11
The discovery of GDC-0941: A potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
2008 · Adrian Folkes, Stewart Baker, et al. · Cancer Research · 5
Pharmacological properties of the PI3 kinase (PI3K) inhibitors PI-540 and PI-620
2008 · Florence I. Raynaud, Angela Hayes, et al. · Cancer Research · 1
320 Identification of potent, selective, soluble and permeable small molecule PI3 kinase inhibitors for the treatment of cancer
2004 · K. Ahmadi, W. Alderton, et al. · European Journal of Cancer Supplements · 1
Abstract 3053: Combination of the MDM2 antagonist ASTX295 and Olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors
2026 · Antonio Morales, Joanna Obacz, et al. · Cancer Research
Supplementary Figure 1 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
Supplementary Figure 3A from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
PDF
Data from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
Supplementary Figure 2 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
Supplementary Table 1 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
Supplementary Figure 3C from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
PDF
Supplementary Figure 3B from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
PDF
Supplementary Figure 3B from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
Supplementary Figure 2 from Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2023 · Florence I. Raynaud, Suzanne A. Eccles, et al.
PDF
Works count: 30
Citation count: 671
H-index: 11
I10-index: 12
Year
Topic
Type